CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 22, 2022 | Series C | €50M | 8 |
Brandon Capital Partners
Jeito Capital |
— | Detail |
Nov 19, 2020 | Series B | €50M | 6 | Vesalius Biocapital Partners | — | Detail |
Aug 5, 2016 | Seed | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Brandon Capital Partners | Yes | Series C |
Jeito Capital | Yes | Series C |
Bayern Kapital | — | Series C |
BioGeneration Ventures | — | Series C |
coparion | — | Series C |
Forbion Capital Partners | — | Series C |
Novartis Venture Fund | — | Series C |
Vesalius Biocapital Partners | — | Series C |
Wachstumsfonds Bayern | — | Series B |